Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients

Zhe Yang, Caicun Zhou, Qiuxiang Ou et al.|Clinical Cancer Research|2018

Cited by 551